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Background: Esophageal squamous cell carcinoma (ESCC), one of the most aggressive 
cancers, is endemic in Sub-Saharan Africa, constituting a major health burden. It has 
the most divergence in cancer incidence globally, with high prevalence reported in East 
Asia, Southern Europe, and in East and Southern Africa. Its etiology is multifactorial, with 
lifestyle, environmental, and genetic risk factors. Very little is known about the role of 
genetic factors in ESCC development and progression among African populations. The 
study aimed to systematically assess the evidence on genetic variants associated with 
ESCC in African populations.
Methods: We carried out a comprehensive search of all African published studies up 
to April 2019, using PubMed, Embase, Scopus, and African Index Medicus databases. 
Quality assessment and data extraction were carried out by two investigators. The 
strength of the associations was measured by odds ratios and 95% confidence intervals.
Results: Twenty-three genetic studies on ESCC in African populations were included 
in the systematic review. They were carried out on Black and admixed South African 
populations, as well as on Malawian, Sudanese, and Kenyan populations. Most studies 
were candidate gene studies and included DNA sequence variants in 58 different genes. 
Only one study carried out whole-exome sequencing of 59 ESCC patients. Sample sizes 
varied from 18 to 880 cases and 88 to 939 controls. Altogether, over 100 variants in 37 
genes were part of 17 case-control genetic association studies to identify susceptibility 
loci for ESCC. In these studies, 25 variants in 20 genes were reported to have a statistically 
significant association. In addition, eight studies investigated changes in cancer tissues 
and identified somatic alterations in 17 genes and evidence of loss of heterozygosity, 
copy number variation, and microsatellite instability. Two genes were assessed for both 
genetic association and somatic mutation.
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INTRODUCTION
Esophageal cancer is an aggressive and fatal cancer of the 
18digestive tract. It accounts for an estimated 455,800 new cases 
and 400,200 deaths per year globally, making it the eighth most 
common cancer in the world (Murphy et al., 2017). The malignant 
tumors are characterized by two major subtypes: esophageal 
squamous cell carcinoma (ESCC), which is the more common 
type and contributes 90%, and esophageal adenocarcinoma 
(EAC) (Kaz and Grady, 2014; Abnet et al., 2017). ESCC 
presents with poor prognosis and low survival rate (<5%) in low 
resource settings (Yazbeck et al., 2016; Murphy et al., 2017). The 
asymptomatic development of ESCC results in diagnosis at late 
stage for patients and is characterized by dysphagia. At this stage, 
treatment is limited to palliative care.
ESCC is endemic in specific geographic locations worldwide 
and has the most divergence in cancer incidence globally, with 
high prevalence reported in East Asia, Southern Europe, as 
well as in Eastern and Southern Africa (Abnet et al., 2017). 
This peculiar distribution draws questions on the specificity 
of certain risk factors to particular populations. The African 
ESCC corridor, which includes Ethiopia, Rwanda, Burundi, 
Malawi, Kenya, Uganda, Tanzania, and South Africa, is an 
ESCC hotspot region (Munishi et al., 2015; Schaafsma et al., 
2015). It has also been reported that in Sub-Saharan Africa, 
ESCC develops in younger patients than in other regions 
(Kayamba et al., 2015).
The etiology of esophageal carcinoma is multifactorial. The 
risk factors reported worldwide comprise several lifestyle and 
environmental and genetic factors (Pink et al., 2011; Sewram et al., 
2014; Chen et al., 2015; Sewram et al., 2016; Huang and Yu, 
2018). Growing evidence supports the hypothesis that genomic 
alterations and epigenetic modifications contribute to tumor 
development (Baba et al., 2017). ESCC has both an inherited 
and cellular genetic basis (Abnet et al., 2017; Coleman et al., 
2018). Familial syndromes associated with increased risk of 
malignancy include tylosis and Fanconi anemia (Abnet et al., 
2017). The majority of genetic studies on ESCC have been 
case-control association studies analyzing single-nucleotide 
polymorphisms (SNPs) in various candidate genes. However, 
the reproducibility of these studies has been low. Some of 
the more common SNPs associated with ESCC have been 
identified in the aldehyde dehydrogenase 2 family gene 
(ALDH2) and an acetaldehyde dehydrogenase gene (ADH1B) 
(Abnet et al., 2017). Variants in these genes have been shown 
to increase susceptibility to ESCC development, and they are 
also associated with alcohol consumption (Abnet et al., 2017). 
Two meta-analyses published in 2018 reported associations 
between the genes MTHFR and GSTT1 and esophageal 
cancer development (He et al., 2018; Kumar and Rai, 2018). 
However, the meta-analyses were done on predominantly 
Asian and Western populations. In recent years, the focus of 
ESCC research in the Western and Asian countries has shifted 
from candidate gene studies to genome-wide association 
studies (GWAS) and whole-exome sequencing (WES) to 
identify variants associated with ESCC. Combined analysis of 
different study designs has provided a better understanding 
of ESCC etiology in Asian populations (Abnet et al., 2017). 
Genes with variants implicated in the development of ESCC in 
these populations include phospholipase c epsilon 1 (PLCE1), 
caspase 8 (CAP8), tumor protein 53 (TP53), and human 
leukocyte antigen (HLA) (Abnet et al., 2017).
The genetic etiology of ESCC in Africa is not well 
understood, since there have been very few studies on ESCC 
in African populations. This is in part due to the unavailability 
of adequate research infrastructure. A lack of comprehensive 
assessment and validation of existing evidence through 
systematic reviews has also contributed to this knowledge gap. 
A number of small studies on African populations have yielded 
varied associations between genetic variants and ESCC. There 
is, therefore, a need to systematically assess the current evidence 
in order to map out the contribution of genetic factors in the 
development of ESCC in African populations using critically 
appraised data.
The aim of the current systematic review was to assess all genetic 
(cross-sectional, case-control, and cohort) studies reporting on 
germline and somatic variants where risk factor estimates were 
calculated. This was achieved through the following: 1) critical 
appraisal of African literature on association of genetic factors 
to ESCC development; 2) comprehensive analysis of genetic 
(germline and somatic) variants in the reported studies; 3) data 
synthesis through pooled analysis, if feasible; and 4) comparison 
of genetic variants identified in African populations to those 
reported in other geographic regions.
MATERIALS AND METHODS
We followed the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines (PRISMA) (Little et al., 
2009). However, because PRISMA is not a quality assessment 
tool, other instruments were used to assess quality control.
Conclusions: Comprehensive large-scale studies on the genetic basis of ESCC are 
still lacking in Africa. Sample sizes in existing studies are too small to draw definitive 
conclusions about ESCC etiology. Only a small number of African populations have been 
analyzed, and replication and validation studies are missing. The genetic etiology of ESCC 
in Africa is, therefore, still poorly defined.
Keywords: esophageal squamous cell carcinoma, genetic association, somatic variant, germline mutation, 
sequence variants, systematic review, African populations
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Data Sources and Search Strategy
We carried out a literature search on all published African 
ESCC studies up to April 2019. We developed a comprehensive 
set of search terms subjectively and iteratively. We searched 
the following electronic bibliographic databases without time 
or language limits: Medline (PubMed), Embase (OViD), 
Scopus, African Index Medicus, and Africa-wide information 
(EbsCOHost). We also checked the reference lists of potentially 
relevant articles for additional citations and used the “related 
citations” search key in PubMed to identify similar papers.
We checked Medline (PubMed) to identify controlled 
vocabulary (MeSH) terms related to esophageal cancer and 
also identified text keywords based on our knowledge of the 
field (Table 1). Medline search terms were modified for other 
electronic databases to conform to their search functions.
Screening for eligible studies was carried out by two authors 
(HS and HK). First, the two authors read the titles and abstracts 
independently and then met to finalize an initial list. Full articles 
of the studies selected based on the initial screening were read 
and assessed for inclusion to the systematic review. Figure 1 
shows the outline for selection of eligible studies.
Quality Control and Data Extraction
Quality of the methodology used in the published studies was 
assessed using a quality assessment tool adapted from the 
STrengthening the REporting of Genetic Association studies 
(STREGA) statement (Little et al., 2009). The quality assessment 
for genetic association studies to identify ESCC susceptibility loci 
included reporting on power calculations, detailed population 
characteristics for cases, description of ESCC diagnosis, screening 
of cases and controls, reporting a measure of association using 
odds ratios, adjustment of population stratification, assessment 
of genotyping error, reporting the Hardy–Weinberg equilibrium, 
correction for multiple testing, and reporting of National Center 
for Biotechnology Information (NCBI) rs numbers for variants 
(Table S1).
For somatic mutation studies, quality assessment included the 
following: description of ESCC diagnosis, reporting of tissues 
used [cancerous (Ca) and normal neighboring tissue (NET)], 
detailed population characteristics, variant classification and 
type, confirmation of variants identified, reporting of amino acid 
change, and use of pathogenicity scoring (Table S2).
Data extraction was carried out by two authors (HS and HK) 
using data extraction forms. Two separate extraction forms were 
prepared for the germline (genetic susceptibility) and somatic 
mutation studies. The data extraction form for the genetic 
susceptibility studies included the following: description of the 
population (age, sex, sample size, smoking, and alcohol use for 
cases and controls separately), genotyping method, statistical 
analysis test, minor allele frequency (MAF), genotype frequency, 
haplotype frequency, and environmental association frequency. 
The somatic mutation study extraction form had the same 
variables excluding gene–environment interaction frequency 
and haplotype frequency.
The South African Admixed Population is reported as mixed 
ancestry in the tables according to how it was reported in the articles.
Data Analysis
A meta-analysis could not be performed as there were only two 
SNPs analyzed in more than one study and even those were 
analyzed in only two independent studies. For a meta-analysis to 
be carried out, SNPs have to be assessed in at least three separate 
case-control studies. TP53 in the somatic variant studies was 
analyzed in four separate studies, but two of the studies had cases 
only with no controls, and the remaining two assessed different 
parts of the gene. The results of this systematic review will, 
therefore, be reported in a descriptive manner.
We were able to find rs numbers for most of the variants even 
if the authors of the original studies did not report them and have 
included them in the tables of this systematic review. We used 
the canonical SNP identifier (rs number) and dbSNP (version 
152; April 2019) database at NCBI (https://www.ncbi.nlm.nih.
gov/snp/) for this. We also determined the locus positions of the 
microsatellite markers reported in a study by Naidoo et al. (2005) 
using the primer-BLAST database at NCBI (https://www-ncbi-
nlm-nih-gov.ez.sun.ac.za/tools/primer-blast).
To determine the linkage disequilibrium (LD) measures between 
the SNPs reported in the same genes, we obtained the imputed data 
set from the Thousand Genomes project (1000 Genomes Release 
Phase 3 2013-05-02) and used bcftools to extract all individuals 
from African populations, not including African Americans, and 
the 77 SNPs discussed here using all synonyms (alternative rs 
IDs) for SNPs (Auton et al., 2015). We obtained a dataset of 504 
individuals and 67 SNPs. We computed all pair-wise r2-values using 
PLINK (v1.09) (Danecek et al., 2011; Chang et al., 2015).
TABLE 1 | Medline (PubMed) search strategy to identify published African 
ESCC literature.
#1 Search cancer or carcinoma or neoplasm* Field: Title/Abstract
#2 Search Esophageal or oesophageal Field: Title/Abstract
#3 #1 and #2
#4 Search “Esophageal cancer” Field: Title/Abstract
#5 Search “oesophageal cancer” or “oesophageal neoplasm*” Field: Title/
Abstract
#6 Search “Esophageal Neoplasms”[Mesh] 
#7 Search “Esophageal Neoplasms” Field: Title/Abstract
#8 Search “Esophageal squamous cell carcinoma” or “oesophageal 
squamous cell carcinoma” or ESCC Field: Title/Abstract
#9 Search ((((#3) OR #4) OR #5) OR #6) OR #7 OR #8
#10 Search “Africa”[Mesh] 
#11 Search algeria OR angola OR benin OR botswana OR burkina faso 
OR burundi OR cameroon OR cape verde OR central african republic 
OR chad OR comoros OR congo OR “Democratic Republic of Congo” 
OR DRC OR djibouti OR equatorial guinea OR egypt OR eritrea OR 
ethiopia OR gabon OR gambia OR ghana OR guinea OR bissau OR 
ivory coast OR (Côte d’ Ivoire) OR jamahiriya OR kenya OR lesotho OR 
liberia OR Libya OR madagascar OR malawi OR mali OR mauritania 
OR mauritius OR mayotte OR morocco OR mozambique OR namibia 
OR niger OR nigeria OR principe OR reunion OR rwanda OR “Sao 
Tome” OR senegal OR seychelles OR “Sierra Leone” OR somalia OR 
“South Africa” OR st helena OR sudan OR swaziland OR tanzania 
OR togo OR tunisia OR uganda OR zaire OR zambia OR zimbabwe 
OR “Central Africa” OR “West Africa” OR “East Africa” OR “Southern 
Africa” OR “South Africa” Field: Title/Abstract
#12 Search (#10) or #11 
#13 Search (#9) AND #12
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RESULTS
Systematic Review Outline
The selection process for all the included studies is shown in 
Figure 1. The initial database search identified 2,235 articles. 
Titles and abstracts of these articles were reviewed, and 2,168 
studies were removed for not being original genetic studies. The 
67 articles that remained were selected for full-text eligibility 
assessment. This process resulted in the removal of 40 articles: 
15 review articles, 18 chromosomal, gene or protein expression 
studies, 4 blood group studies, 1 duplicate, and 2 abstracts. 
A total of 27 full articles were then assessed for eligibility, and four 
articles  were removed for not meeting the criteria, as follows: 
one study had no cancer patients/cases (Adams et al., 2003), one 
focused on the Chinese population (Li et al., 2016), while one 
focused on protein expression (Jaskiewicz and De Groot, 1994; 
FIGURE 1 | Outline of the systematic review.
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Huang and Yu, 2018), and the other was a mathematical model 
study (Uys and Van Helden, 2003). In the end, 23 studies were 
included and analyzed in the systematic review.
Study Characteristics
The characteristics of all the genetic susceptibility and somatic 
variant studies included are shown in Tables 2 and 3, respectively. 
The 23 studies included in the study were published between 
1990 and 2019. There were 17 genetic susceptibility and eight 
somatic variant studies. Two studies reported on both genetic 
susceptibility and somatic variants.
Genetic Susceptibility Studies
The 17 genetic susceptibility studies (Table 2) were all case-control 
studies (Dietzsch et al., 2003; Vos et al., 2003; Dandara et al., 2005; 
Li et al., 2005; Zaahl et al., 2005; Chelule et al., 2006; Dandara 
et al., 2006; Li et al., 2008; Li et al., 2010; Bye et al., 2011; Matejcic 
et al., 2011; Bye et al., 2012; Eltahir et al., 2012; Strickland et al., 
2012; Vogelsang et al., 2012; Matejcic et al., 2015; Chen et al., 
2019) published between 2003 and 2019. Sixteen articles reported 
on the South African population and one article on the Sudanese 
population. The majority (13/17; 76%) of the studies reported on 
the main subject characteristics (ethnicity, sex, age, and type of 
clinical assessment). Sample sizes for ESCC patients ranged from 
18 to 880 with six of the studies having over 200 patient samples. 
Sample sizes for controls ranged from 88 to 939 with nine of the 
studies having over 200 control samples. It is difficult to estimate 
the total number of patients analyzed in these 17 studies, since it 
appears that the same authors used the same sample set for different 
SNPs in different publications. Our assessment showed that Bye 
et al. (2011) and Bye et al. (2012) used the same participants. 
In  addition, studies by Li et al. (2005) and Li et al. (2008) used 
the same participants as Dandara et al. (2005). The remaining 12 
studies do not seem to have any obvious sample overlap.
Altogether, 16 out of 17 studies clinically assessed for ESCC 
through histology. None of the studies clinically assessed controls 
for ESCC with the exception of one study (Strickland et al., 
2012), which assessed controls using a brush biopsy. Nine studies 
reported on smoking and alcohol consumption status for all 
participants (Dandara et al., 2005; Li et al., 2005; Dandara et al., 
2006; Li et al., 2008 Li et al., 2010; Bye et al., 2012; Vogelsang et 
al., 2012; Matejcic et al., 2015; Chen et al., 2019), while three (Bye 
et al., 2011; Matejcic et al., 2011; Strickland et al., 2012) reported 
those risk factors for only the ESCC patients.
The Hardy–Weinberg equilibrium deviation was assessed in 11 
(65%) studies; however, only six (35%) of the studies reported power 
calculations, and three (18%) studies reported the evaluation of a 
genotyping error. Detailed characteristics of the study population 
were reported in 12 of the studies for cases and 10 for controls. 
Correction for multiple testing was reported in only seven (41%) 
studies. NCBI rs numbers were reported in eight (47%) studies. Our 
quality assessment scoring had 11 items (Table S1), and each item 
had a weight of 1 point; therefore, total maximum quality score was 
11. Overall, only seven of the 17 (41%) studies scored half or above 
half (5.5). The highest score was 9 (Vogelsang et al., 2012; Chen et al., 
2019), and the lowest score was 1 (Vos et al., 2003; Zaahl et al., 2005).
Somatic Variant Studies
Somatic variant studies (Table 3) constituted of eight studies 
published between 1990 and 2016 (Victor et al., 1990; Gamieldien 
et al., 1998; Dietzsch and Parker, 2002; Dietzsch et al., 2003; Vos 
et al., 2003; Naidoo et al., 2005; Patel et al., 2011; Liu et al., 2016). 
A total of 455 patients were assessed, with the control group 
comprising 200 NET and 146 blood samples. Of the 455 patient 
samples, one was reported to be an adenocarcinoma from one 
study; therefore, the exact ESCC patient population was 454. The 
study populations were from South Africa, Kenya, and Malawi.
Clinical diagnosis of ESCC was determined by histology in 
five (75%) studies, and the remaining three did not report on 
how clinical assessment was done. Four (50%) studies reported 
using both cancer tissue and NET for assessment. Three of these 
studies had an equal number of cancer tissue and NET samples. 
Two (25%) studies did not have any control samples, and the 
remaining two (25%) studies collected blood samples only as 
controls. Only two studies reported on smoking and alcohol 
consumption status. On patient characteristics, age and sex were 
reported in six (75%) of the studies. Variant classification and 
type were reported in all of the studies, but confirmation of results 
was reported in only two studies. No studies used pathogenicity 
scoring. Amino acid change was also reported in only two of the 
studies. Our quality assessment score had seven items (Table S2), 
and each item had a weight of 1 point; therefore, total maximum 
score for the quality assessment was 7. Overall, six of the eight 
(75%) studies scored half or above half (3.5). The highest score 
was 6 (Gamieldien et al., 1998), and the lowest score was 0 
(Victor et al., 1990).
Description of Genes Studied
A total of 58 genes were investigated in the 23 studies, which 
were selected for the systematic review, with 37 genes studied in 
the genetic susceptibility studies and 23 in the somatic variant 
studies. Two genes were investigated in both studies. In addition, 
the somatic studies investigated six genetic loci without specific 
gene names. A summary of SNPs analyzed in the genetic 
susceptibility studies is shown in Table 4. Over 100 SNPs were 
analyzed, and 25 SNPs were reported to be associated with ESCC 
(four SNPs using p values only, and 21 SNPs using p values and 
odds ratios). The 25 SNPs were in 20 genes: ADH1B, ADH3, 
ALDH2, AR, CASP8, CHEK2, CP, CYP2E1, CYP3A5, GSTT2B, 
MGMT, MLH3, MSH3, NAT2, PTGS2 (also known as COX-2), 
PLCE1, PMS1, RUNX1, SLC11A1, and TP53. The associations 
with all 25 SNPs were identified in South African populations, 
while none were found in the Sudanese population.
Table 5 shows a summary of the pathways for the 20 genes. All 
the genes encode for proteins. Three of the genes, ADH1B, ADH3, 
and ALDH2, are involved in alcohol metabolism (Li et al., 2008; 
Bye et al., 2011). Three mismatch repair genes, MLH3, MSH3, and 
PMS1, play a role in genomic integrity (Vogelsang et al., 2012). 
They are reported to also play a role in carcinogenesis. MGMT is 
involved in cell defense against mutagens, and mutations in the 
gene are reported to be associated with cancer formation (Bye et 
al., 2011). NAT2 and GSTT2B play a role in the activation and 
deactivation of drugs and carcinogens, with reports of mutations 
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TABLE 2 | Characteristics of genetic susceptibility studies for ESCC in African populations.
Study
(PMID)
Location Year Population Age, y (SD) Sample size Sex, cases  
n (%)
Sex, ctrl  
n (%)
Clinical 
assessment
Analysis 
method
Smoking  
n (%)
Alcohol n (%)
Cases Ctrl Cases Ctrl Male Female Male Female Cases Ctrl Cases Ctrl Cases Ctrl
Bye et al., 
2011
(21926110)
South 
Africa
2011 Black 59.8 (11.3) – 358 477 182 (50.8) 176 (49.2) – – Histology – TaqMan Assay 228 (63.7) – 228 (63.7) –
Mixed ancestry 60.5 (10.6) – 201 427 131 (65.2) 70 (34.8) – – Histology – TaqMan Assay 189 (94.1) – 163 (81.1) –
Bye et al., 
2012 
(22865593)
South 
Africa
2012 Black 59.8 (11.3) 48.8 (16.7) 407 849 199 (48.9) 208 (51.1) 335 (39.5) 511 (60.2) Histology – TaqMan Assay 
and KASP
242 (59.5) 333 (39.2) 253 (62.2) 452 (53.2)
Mixed ancestry 60.6 (10.6) 46.7 (16.8) 257 860 165 (64.2) 91 (35.4) 309 (35.9) 551 (64.1) Histology – TaqMan Assay 
and KASP
240 (93.4) 597 (69.4) 212 (82.5) 419 (48.7)
Chelule et al., 
2006 
(17264406)
South 
Africa
2006 Black 18–741 18–74 70 261 – – – – Histology – PCR-RFLP – – – –
Chen et al., 
2019 
(30753320)
South 
Africa
2019 Black7 60.2 (11.3) 48.9 (16.8) 591 852 284 (48.1) 307 (51.9) 342 (40.1) 507 (59.5) Histology – TaqMan Assay 364 (61.6) 338 (39.7) 370 (62.6) 458 (53.7)
Black8 58.2 (10.2) 50.0 (15.5) 880 939 545 (61.9) 332 (37.7) 240 (25.6) 698 (74.3) Histology iPLEX and 
TaqMan Assays
598 (68.0)  333 (35.5) 473 (53.8) 633 (67.4)
Dandara 
et al., 2005 
(15978331)
South 
Africa
2005 Black – – 142 178 – – – – Histology – PCR-RFLP 179 162 171 160
Mixed ancestry – – 99 94 Histology PCR-RFLP
Dandara et al., 
2006 
(16272171)
South 
Africa
2006 Black 61.23 61.85 145 194 85 (59) 60 (41) 111 (57) 83 (43) Histology – PCR-RFLP 95 (65) 123 (63) 98 (68) 127 (65)
Mixed ancestry 61.49 69.53 100 94 78 (78) 22 (22) 45 (48) 49 (52) Histology – PCR-RFLP 93 (93) 74 (79) 73 (73) 45 (48)
Dietzsch 
et al., 2003 
(12925954)
South 
Africa
2003 Black and 
mixed ancestry
59.6 58.7 582 226 44 14 167 59 – – PCR and
PAGE
Eltahir 
et al., 2012 
(23053979)
Sudan 2012 18 235 Histology PCR-RFLP
Li et al., 2005 
(15899651)
South 
Africa
2005 Black and 
mixed ancestry
61.1 (10.5) 65.7 (10.2) 189 198 – – – – Histology – PCR-SSCP and 
DNA sequencing
144 (76) 122 (62) 133 (70) 114 (58)
Li et al., 2008 
(18254707)
South 
Africa
2008 Black3 – – 142 178 – – – – Histology – PCR- RLFP 179 162 71 160
Mixed3 
ancestry
101 100 Histology PCR-RFLP
Li et al., 2010 
(20540773)
South 
Africa
2010 Black3 61.23 61.85 145 194 85 (59) 60 (41) 111 (57) 83 (43) Histology – PCR-RFLP 95 (65) 123 (63) 98 (68) 127 (65)
Mixed3 
ancestry
61.49 69.53 100 94 78 (78) 22 (22) 45 (48) 49 (52) Histology – PCR- RFLP 93 (93) 74 (79) 73 (73) 45 (48)
Matejcic 
et al., 2011 
(22216261)
South 
Africa
2011 Black – – 330 479 – – – – Histology – TaqMan 
assay and gel 
electrophoresis
210 – 204 –
Mixed ancestry – – 232 428 – – – – Histology – TaqMan 
assay and gel 
electrophoresis
216 – 189 –
Matejcic 
et al., 2015 
(26447020)
South 
Africa
2015 Black 59.6
(10.7)
56.7
(15.0)
463 480 229 (49) 234 (51) 235 (49) 245 (51) Histology – TaqMan assay 280 (60) 222 (46) 286 (62) 278 (58) 
Mixed ancestry 60.7 (10.3) 57.7 (14.3) 269 288 177 (66) 92 (34) 178 (62) 110 (38) Histology – TaqMan Assay 250 (93) 226 (78) 215 (80) 172 (60)
Strickland 
et al., 2012 
(21901748)
South 
Africa
2012 Black 59/664 – 96 88 48 48 – – Histology Brush
biopsy
HEX SSCP and 
DNA sequencing
58 – 58 –
Vogelsang 
et al., 2012 
(22623965)
South 
Africa
2012 Black 59.8 (11.3) 56.1 (16.2) 3455 344 166 (48.1) 179 (51.9) 120 (34.9) 224 (65.1) Histology – Allele-specific 
quantitative PCR
209 (60.6) 117 (34.0) 160 (46.4) 92 (26.7)
Mixed ancestry 60.7 (10.2) 56.8 (16.5) 2056 266 136 (66.3) 69 (33.7) 82 (30.8) 184 (69.2) Histology – Allele-specific 
quantitative PCR
189 (92.2) 162 (60.9) 118 (57.6) 38 (14.3)
(Continued)
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TABLE 2 | Continued
Study
(PMID)
Location Year Population Age, y (SD) Sample size Sex, cases  
n (%)
Sex, ctrl  
n (%)
Clinical 
assessment
Analysis 
method
Smoking  
n (%)
Alcohol n (%)
Cases Ctrl Cases Ctrl Male Female Male Female Cases Ctrl Cases Ctrl Cases Ctrl
Vos et al., 
2003 
(12550754)
South 
Africa
2003 Black 57 (11) 57 (11) 74 118 – – – – Histology – SSCP and DNA 
sequencing
– – – –
Zaahl 
et al., 2005 
(15860357)
South 
Africa
2005 Mixed ancestry – – 105 110 82 23 43 67 Histology – SSCP and DNA 
sequencing
– – – –
1Only range of age was reported for the combined group of cases and controls.
257 had ESCC.
3Same population as in Dandara et al. (2005) study.
459+/–13 for male (n = 48) and 66+/– (n = 48) for female patients.
5326 had ESCC.
6182 had ESCC.
7Western and Eastern Cape Province Black Population.
8Gauteng Province Black Population.
Ctrl, controls; ESCC, esophageal squamous cell carcinoma; HEX, heteroduplex; KASP, competitive allele specific PCR; PAGE, polyacrylamide gel electrophoresis; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; 
SD, Standard deviation; SSCP, single-strand conformation polymorphism.
TABLE 3 | Characteristics of studies on somatic changes in ESCC in African populations.
Study (PMID) Country Year Population Sample size Age, y 
(SD)
Sex  
n (%)
Clinical assessment Analysis method Smoking 
n (%)
Alcohol n 
(%)
Ca NET Blood Cases Male Female Ca NET
Dietzsch and Parker, 2002 
(12435113)
South Africa 2002 Black 33 33 – 57.4 23 (70) 10 (30) Histology – PCR and DNA 
sequencing analysis
– –
Dietzsch et al., 2003 
(12925954)
South Africa 2003 Black and 
mixed ancestry
581 58 – 59.6 29 (67) 14 (33) – – PCR and PAGE – –
Gamieldien et al., 1998 
(9808520)
South Africa 1998 Black 76 9 50 57 (11) 49 (65) 27 (35) Histology Histology PCR and HEX-SSCP – –
Liu et al., 2016 (29148985) Malawi 2016 Malawian 59 – 59 56 27 (45.8) 31 (52.5) Histology - WES 24 (40.7) 14 (23.7)
Naidoo et al., 2005 
(15735161)
South Africa 2005 South African 100 100 – 56 53 (54) 45 (46) Histology Histology PCR – –
Patel et al., 2011 
(22040862)
Kenya 2011 Kenyan 28 – – 56.03 
(12.30)
13 (46) 15 (54) – – PCR and DNA 
sequencing
6 (21) 10 (36)
Victor et al., 1990 
(2199031)
South Africa 1990 Black and 
mixed ancestry
27 – – – – – – – PCR and dot blot 
hybridization
– –
Vos et al., 2003 
(12550754)
South Africa 2003 South African 74 – 37 – – – Histology – SSCP and DNA 
sequencing
– –
Ca, cancer tissue; HEX-SSCP, heteroduplex single-strand conformation polymorphism; NET, neighboring tissue; PAGE, polyacrylamide gel electrophoresis; PCR, polymerase chain reaction; WES, whole exome sequencing.
157 had ESCC and 1 had adenocarcinoma.
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TABLE 4 | Summary of studies investigating genetic susceptibility of ESCC in African populations.
Gene Variant (rs 
number)
Study (PMID) Population ESCC Controls Effect 
allele
Findings and  
Comments2
n MAF n MAF
ADH1B rs1229984 
(Arg48His) 
Bye et al., 2011 
(21926110)
Black South African 358 0 477 0 Not informative
Bye et al., 2011 
(21926110)
Mixed ancestry 
South African
201 0.054 427 0.098 A OR = 0.52 (0.32–0.86) 
p = 0.009
ADH2 ADH2*1/*2/*3 Li et al., 2008 
(18254707)
Black South African 142 0.01 174 0.01 Not informative
Li et al., 2008 
(18254707) 
Mixed ancestry 
South African
96 0.03 94 0.03 Not informative
ADH3 ADH3*1/*2 Li et al., 2008 
(18254707)
Black South African 141 0.46 174 0.32 NS
Li et al., 2008 
(18254707)
Mixed ancestry 
South African
96 0.38 94 0.31 *2 OR = 1.80; p = 0.0004
ADH7 rs1573496 
(Gly92Ala)
Bye et al., 2011 
(21926110)
Black South African 358 0 477 0.001 Not informative
Bye et al., 2011 
(21926110)
Mixed ancestry 
South African
201 0.014 427 0.02 NS
ALDH2 rs671 
(Glu504Lys)
Bye et al., 2011 
(21926110)
Black South African 358 0 477 0 Not informative
Bye et al., 2011 
(21926110)
Mixed ancestry 
South African
201 0 427 0 Not informative
rs441
(-261 C/T)
Bye et al., 2011 
(21926110)
Black South African 358 0.154 477 0.145 NS
Bye et al., 2011 Mixed ancestry 
South African
201 0.18 427 0.194 NS
rs886205 (+82 
A/G)
Bye et al., 2011 
(21926110)
Black South African 358 0.247 477 0.252 NS
Bye et al., 2011 
(21926110)
Mixed ancestry 
South African
201 0.402 427 0.489 G OR = 0.70 (0.55–0.89); 
p = 0.004
ALDH2*1/*2 Li et al., 2008 
(18254707)
Black South African 142 0.10 174 0.04 *2 OR = 2.35; p = 0.008
Li et al., 2008 
(18254707)
Mixed ancestry 
South African
101 0.03 1004 0.04 Not informative
rs4767364 (A/G) Chen et al., 2019 
(30753320)
Black South African5 880 0.12 939 0.11 NS
ALS2CR12 rs13016963 (G/A) Chen et al., 2019 
(30753320)
Black South African4 591 0.35 852 0.35 NS
Chen et al., 2019 
(30753320)
Black South African5 880 0.39 939 0.38 NS
rs10201587 (A/G) Chen et al., 2019 
(30753320)
Black South African5 880 0.38 939 0.39 NS
AR CAG-repeat in 
exon 1
Dietzsch et al., 2003 
(12925954)
Black South African 
males
29 109 NS
Dietzsch et al., 2003 
(12925954)
Mixed ancestry 
South African males
15 58 NS
GGC-repeat in 
exon 1
Dietzsch et al., 2003 
(12925954)
Black South African 
males
29 109 (GGC)≤16 OR = 2.7 (1.14–6.36); 
p = 0.018
Dietzsch et al., 2003 
(12925954)
Mixed ancestry 
South African males
15 58 NS
ATP1B2/
TP53
rs1642764 (C/T) Chen et al., 2019 
(30753320)
Black South African4 591 0.21 852 0.20 NS
Chen et al., 2019 
(30753320)
Black South African5 880 0.18 939 0.18 NS
rs1641511 (A/G) Chen et al., 2019 
(30753320)
Black South African5 880 0.39 939 0.42 NS
C20orf54 rs13042395 Bye et al., 2012 
(22865593) 
Black South African 407 0.002 849 0.005 Not informative
Bye et al., 2012 
(22865593)
Mixed ancestry 
South African
257 0.067 860 0.068 NS
(Continued)
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TABLE 4 | Continued
Gene Variant (rs 
number)
Study (PMID) Population ESCC Controls Effect 
allele
Findings and  
Comments2
n MAF n MAF
CASP8 rs1045485 
(Asp302His)
Bye et al., 2011 
(21926110)
Black South African 358 0.154 477 0.152 NS
Bye et al., 2011 
(21926110)
Mixed ancestry 
South African
201 0.169 427 0.126 C OR = 1.42 (1.01–1.98); 
p = 0.040
rs3834129
(-652 6N ins/del)
Bye et al., 2011 
(21926110)
Black South African 358 0.518 477 0.502 NS
Bye et al., 2011 
(21926110)
Mixed ancestry 
South African
201 0.385 427 0.386 NS
rs10931936 (C/T) Chen et al., 2019 
(30753320)
Black South African4 591 0.19 852 0.20 NS
Chen et al., 2019 
(30753320)
Black South African5 880 0.22 939 0.20 NS
CHEK2 rs4822983 (C/T) Chen et al., 2019 
(30753320)
Black South African4 591 0.46 852 0.39 T OR = 1.32 (1.12–1.56); 
p = 0.001
Chen et al., 2019 
(30753320)
Black South African5 880 0.43 939 0.42 NS
rs1033667 (C/T) Chen et al., 2019 
(30753320)
Black South African4 591 0.44 852 0.38
T
OR = 1.30 (1.10–1.53)
P = 0.002
Chen et al., 2019 
(30753320)
Black South African5 880 0.42 939 0.39 NS
CP rs34053109 
(C/G)
Strickland et al., 2012 
(21901748)
Black South African 84  0 85 0.01 Not informative
rs17838834 (T/C) Strickland et al., 2012 
(21901748)
Black South African 90 0.33 85 0.23 NS
rs701749 (C/T) Strickland et al., 2012 
(21901748)
Black South African 79 0.01 78 0.02 Not informative
rs17838833 
(delT)
Strickland et al., 2012 
(21901748)
Black South African 79 0.01 78 0 Not informative
rs17838832 (T/C) Strickland et al., 2012 
(21901748)
Black South African 80 0.33 78 0.3 NS
rs34334174 (C/T) Strickland et al., 2012 
(21901748)
Black South African 80 0.14 78 0.08 NS
5’UTR-308G/A Strickland et al., 2012 
(21901748)
Black South African 52 0.05 64 0 A p = 0.012; sample size very 
small
rs17838831 (A/G) Strickland et al., 2012 
(21901748)
Black South African 53 0.21 64 0.22 NS
rs138512757 
(Thr83) 
Strickland et al., 2012 
(21901748)
Black South African 92 0.02 84 0.01 Not informative
rs35438054 
(Val223)
Strickland et al., 2012 
(21901748)
Black South African 95 0.01 85 0.01 Not informative
rs797045480 
(Val246Ala) 
Strickland et al., 2012 
(21901748)
Black South African 95 0.01 85 0 Not informative
rs34067682
(IVS4-14C/T)
Strickland et al., 2012 
(21901748)
Black South African 84 0.12 83 0.12 NS
rs34624984
(Arg367Cys)
Strickland et al., 2012 
(21901748)
Black South African 94 0.02 86 0.01 Not informative
rs34237139
(Tyr425)
Strickland et al., 2012 
(21901748)
Black South African 91 0.01 87 0 Not informative
rs35272481 
(IVS7+9T/C)
Strickland et al., 2012 
(21901748)
Black South African 91 0.01 87 0 Not informative
rs701753
(D544E)
Strickland et al., 2012 
(21901748)
Black South African 95 0.23 81 0.27 NS
rs147192657
(Gly633 T/C)
Strickland et al., 2012 
(21901748)
Black South African 88 0.07 84 0 C p = 0.0004
rs16861582
(IVS15-12T/C)
Strickland et al., 2012 
(21901748)
Black South African 93 0,44 88 0.41 NS
(Continued)
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TABLE 4 | Continued
Gene Variant (rs 
number)
Study (PMID) Population ESCC Controls Effect 
allele
Findings and  
Comments2
n MAF n MAF
CYP2E1 CYP2E1*1 (c1)/
CYP2E1*5 (c2)
Chelule et al., 2006 
(17264406)
Black South African 30 0.04 331 0.06 Limited power
-1053C/T Li et al., 2005 
(15899651) 
Black and Mixed 
ancestry South 
African
189 0.01 198 0.02 NS
-1293G/A Li et al., 2005 
(15899651)
Black and Mixed 
ancestry South 
African
189 0.01 198 0.03 NS
7632T/A Li et al., 2005 
(15899651)
Black and Mixed 
ancestry South 
African
189 0.18 198 0.07 A OR = 5.90 (3.25–10.7); 
p = 0.001 for genotype 
distribution
CYP3A5 CYP3A5*1 Dandara et al., 2005 
(15978331)
Black South African 142 0.627 178 0.638 NS
Dandara et al., 2005 
(15978331)
Mixed ancestry 
South African
99 0.384 94 0.287 NS
CYP3A5*3 
(6986A/G)
Dandara et al., 2005 
(15978331)
Black South African 142 0.155 178 0.138 NS
Dandara et al., 2005 
(15978331)
Mixed ancestry 
South African
99 0.475 94 0.590 G OR = 0.60 (0.39–0.94); 
p = 0.025
CYP3A5*6 
(1490G/A)
Dandara et al., 2005 
(15978331)
Black South African 142 0.190 178 0.213 NS
Dandara et al., 2005 
(15978331)
Mixed ancestry 
South African
99 0.136 94 0.122 NS
CYP3A5*7 
(27131-32insT; 
frameshift)
Dandara et al., 2005 
(15978331)
Black South African 142 0.028 178 0.011 NS
Dandara et al., 2005 
(15978331)
Mixed ancestry 
South African
99 0.005 94 0 Not informative
CYP3A5 all 
variants
Dandara et al., 2005 
(15978331)
Black South African 142 0.373 178 0.441 NS
Dandara et al., 2005 
(15978331)
Mixed ancestry 
South African
99 0.616 94 0.713 OR = 0.65 (0.42–0.99); 
p = 0.045
FAS rs1800682
(-670 G > A)
Bye et al., 2011 
(21926110)
Black South African 358 0.219 477 0.225 NS
Bye et al., 2011 
(21926110)
Mixed ancestry 
South African
201 0.356 427 0.406 NS
rs2234767
(-1377 G > A)
Bye et al., 2011 
(21926110)
Black South African 358 0.096 477 0.072 NS
Bye et al., 2011 
(21926110)
Mixed ancestry 
South African
201 0.139 427 0.183 NS
FASL rs763110
(-844 T > C)
Bye et al., 2011 
(21926110)
Black South African 358 0.192 477 0.189 NS
Bye et al., 2011 
(21926110)
Mixed ancestry 
South African
201 0.416 427 0.386 NS
GSTP1 rs1695
(Ile105Val)
Matejcic et al., 2011 Black South African 325 0.518 474 0.534 NS
rs1695
(Ile105Val)
Matejcic et al., 2011 Mixed ancestry 
South African
229 0.454 428 0.438 NS
rs1695
(Ile105Val)
Li et al., 2010 
(20540773)
Black South African 0.39 0.37 NS
rs1695
(Ile105Val)
Li et al., 2010 
(20540773)
Mixed ancestry 
South African
0.38 0.41 NS
rs1138272
(Ala114Val)
Li et al., 2010 
(20540773) 
Black South African 0.22 0.07 NS
rs1138272
(Ala114Val)
Li et al., 2010 
(20540773) 
Mixed ancestry 
South African
0.19 0.03 NS
GSTT1 Deletion allele Matejcic et al., 2011 
(22216261)
Black South African 311 0.574 462 0.554 NS
Matejcic et al., 2011 
(22216261)
Mixed ancestry 
South African
217 0.493 414 0.495 NS
(Continued)
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TABLE 4 | Continued
Gene Variant (rs 
number)
Study (PMID) Population ESCC Controls Effect 
allele
Findings and  
Comments2
n MAF n MAF
GSTT2B Deletion allele Matejcic et al., 2011 
(22216261)
Black South African 320 0.336 461 0.371 NS
Matejcic et al., 2011 
(22216261)
Mixed ancestry 
South African
226 0.418 425 0.501 OR = 0.71 (0.57–0.90); 
p = 0.004
MGMT rs12917
(Leu84Phe)
Bye et al., 2011 
(21926110)
Black South African 358 0.189 477 0.195 NS
Bye et al., 2011 
(21926110)
Mixed ancestry 
South African
201 0.222 427 0.168 OR = 1.41 (1.05–1.91); 
p = 0.023
MLH1 rs13320360
(c.546-191T/C)
Vogelsang et al., 2012 
(22623965)
Black South African 343 0.15 340 0.17 NS
Vogelsang et al., 2012 
(22623965)
Mixed ancestry 
South African
203 0.07 264 0.06 NS
MLH3 rs28756991
(Arg797His)
Vogelsang et al., 2012 
(22623965)
Black South African 345 0.11 342 0.12 NS
Vogelsang et al., 2012 
(22623965)
Mixed ancestry 
South African
205 0.09 264 0.4 G OR = 2.07 (1.04–4.12); 
p = 0.038
MSH2 rs17217772
(Asn127Ser) 
Vogelsang et al., 2012 
(22623965)
Black South African 341 0.06 343 0.06 NS
Vogelsang et al., 2012 
(22623965)
Mixed ancestry 
South African
204 0.03 264 0.03 NS
rs10188090
(c.2635-765G/A)
Vogelsang et al., 2012 
(22623965)
Black South African 343 0.09 342 0.10 NS
Vogelsang et al., 2012 
(22623965)
Mixed ancestry 
South African
205 0.31 265 0.33 NS
rs3771280
(c.1510+118T/C)
Vogelsang et al., 2012 
(22623965)
Black South African 344 0.11 339 0.12 NS
Vogelsang et al., 2012 
(22623965)
Mixed ancestry 
South African
202 0.35 266 0.37 NS
MSH3 rs26279
(Ala1045Thr)
Vogelsang et al., 2012 
(22623965)
Black South African 341 0.40 344 0.43 NS
Vogelsang et al., 2012 
(22623965)
Mixed ancestry 
South African
204 0.38 263 0.32 A OR = 2.71 (1.34–5.50); 
p = 5.71×10-3
rs1428030
(c.1341-
12568A/G)
Vogelsang et al., 2012 
(22623965)
Black South African 342 0.29 342 0.27 NS
Vogelsang et al., 2012 
(22623965)
Mixed ancestry 
South African
201 0.23 264 0.20 NS
rs1805355
(Pro231Pro)
Vogelsang et al., 2012 
(22623965)
Black South African 343 0.28 339 0.29 NS
Vogelsang et al., 2012 
(22623965)
Mixed ancestry 
South African
203 0.24 265 0.22 NS
NAT1 rs1057126
(1088T > A 
NAT1*10)
Matejcic et al., 2015 
(26447020)
Black South African 463 54.8 480 57.7 NS
Matejcic et al., 2015 
(26447020)
Mixed ancestry 
South African
269 43.4 288 40.1 NS
rs15561 (1095C 
> A NAT1*10, 
NAT1*3)
Matejcic et al., 2015 
(26447020)
Black South African 463 55.7 480 57.7 NS
Matejcic et al., 2015 
(26447020)
Mixed ancestry 
South African
269 46.5 288 43 NS
NAT2 rs1799930
(590G/A NAT2*6)
Matejcic et al., 2015 
(26447020)
Black South African 463 24.7 480 21.4 NS
Matejcic et al., 2015 
(26447020)
Mixed ancestry 
South African
269 22.4 288 22 NS
rs1801280
(341T/C NAT2*5)
Matejcic et al., 2015 
(26447020)
Black South African 463 27.1 480 29 NS
Matejcic et al., 2015 
(26447020)
Mixed ancestry 
South African
269 25.2 288 33.2 C 0R = 0.57 (0.38–0.87) 
p = 0.01
rs1799931
(857G/A NAT2*7)
Matejcic et al., 2015 
(26447020)
Black South African 463 0.01 480 0.05 Not informative
Matejcic et al., 2015 
(26447020)
Mixed ancestry 
South African
269 0.05 288 0.04 NS
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TABLE 4 | Continued
Gene Variant (rs 
number)
Study (PMID) Population ESCC Controls Effect 
allele
Findings and  
Comments2
n MAF n MAF
rs1801279
(191G/A 
NAT2*14)
Matejcic et al., 2015 
(26447020)
Black South African 463 0.053 480 0.063 NS
Matejcic et al., 2015 
(26447020)
Mixed ancestry 
South African
269 0.038 288 0.023 NS
UNC5CL rs10484761 (G/A) Bye et al., 2012 
(22865593)
Black South African 407 0.467 849 0.477 NS
Bye et al., 2012 
(22865593)
Mixed ancestry 
South African
257 0.354 860 0.314 NS
PTGS2 rs20417
(-765 G/C)
Bye et al., 2011 
(21926110)
Black South African 358 0.471 477 0.513 NS
Bye et al., 2011 
(21926110)
Mixed ancestry 
South African
201 0.376 427 0.321 NS
rs689466
(-1195 A/G)
Bye et al., 2011 
(21926110)
Black South African 358 0.064 477 0.053 NS
Bye et al., 2011 
(21926110)
Mixed ancestry 
South African
201 0.103 427 0.155 G OR = 0.63 (0.43–0.91); 
p = 0.014
PDE4D rs10052657
(C/A)
Bye et al., 2012 
(22865593)
Black South African 407 0.137 849 0.128 NS
Bye et al., 2012 
(22865593)
Mixed ancestry 
South African
257 0.175 860 0.155 NS
PLCE1 rs2274223
(His1927Arg)
Bye et al., 2012 
(22865593) 
Black South African 407 0.416 849 0.403 NS
Bye et al., 2012 
(22865593)
Mixed ancestry 
South African
257 0.437 860 0.40 NS
rs17417407
(Arg548Leu)
Bye et al., 2012 
(22865593)
Black South African 407 0.166 849 0.211 T OR = 0.74 (0.60–0.93); 
p = 0.008
Bye et al., 2012 
(22865593)
Mixed ancestry 
South African
257 0.174 860 0.18 NS
rs1438095332
(5’UTR 14 bp 
indel)
Bye et al., 2012 
(22865593)
Black South African 321 0.234 456 0.242 NS
rs199781223 
(Gly1199Ser)
Bye et al., 2012 
(22865593)
Black South African 321 0.053 449 0.045 NS
rs37655253
(Ile1777Thr)
Bye et al., 2012 
(22865593)
Black South African 316 0.472 452 0.463 NS
rs58539480
(Pro1890Leu)
Bye et al., 2012 
(22865593)
Black South African 307 0.073 429 0.064 NS
rs17417407 (G/T) Chen et al., 2019 
(30753320)
Black South African4 591 0.17 852 0.21 T OR = 0.76 (0.60–0.95); 
p = 0.014
Chen et al., 2019 
(30753320)
Black South African5 880 0.19 939 0.19 NS
rs7084339 (G/A) Chen et al., 2019 
(30753320)
Black South African5 880 0.48 939 0.46 NS
rs3765524 (T/C) Chen et al., 2019 
(30753320)
Black South African4 591 0.47 852 0.47 NS
Chen et al., 2019 
(30753320)
Black South African5 880 0.48 939 0.46 NS
rs2274223 (A/G) Chen et al., 2019 
(30753320)
Black South African4 591 0.42 852 0.40 NS
Chen et al., 2019 
(30753320)
Black South African5 880 0.41 939 0.43 NS
rs11187850 (A/G) Chen et al., 2019 
(30753320)
Black South African5 880 0.21 939 0.19 NS
PMS1 rs5742938
(c.-21+639G/A)
Vogelsang et al., 2012 
(22623965)
Black South African 345 0.18 344 0.15 NS
Vogelsang et al., 2012 
(22623965)
Mixed ancestry 
South African
203 0.43 266 0.48 A OR = 1.73 (1.07–2.79); 
p = 0.027
rs13404927
(c.699+3331G/A)
Vogelsang et al., 2012 
(22623965)
Black South African 342 0.18 339 0.19 NS
Vogelsang et al., 2012 
(22623965)
Mixed ancestry 
South African
204 0.14 264 0.12 NS
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Genetics of Esophageal Carcinoma in AfricaSimba et al.
13 August 2019 | Volume 10 | Article 642Frontiers in Genetics | www.frontiersin.org
being associated with carcinogenesis (Matejcic et al., 2015). Genes 
regulating cell apoptosis are TP5, CHEK2, and CASP8 (Vos et al., 
2003; Bye et al., 2011; Eltahir et al., 2012; Chen et al., 2019). TP53 
and CHEK2 are also involved in gene expression and DNA repair. 
Regulation of gene expression is facilitated by PLCE1 and SLC11A1 
(Zaahl et al., 2005; Bye et al., 2012). The AR gene regulates the sex 
hormones, androgens (Dietzsch et al., 2003), while CYP2E1 and 
CYP3A5 are involved in steroid, cholesterol, and lipid synthesis 
(Dandara et al., 2005; Li et al., 2005; Chelule et al., 2006). CYP2E1 
also metabolizes drugs and has been implicated in carcinogenesis. 
CP facilitates transportation of iron from organs into the blood 
cells; RUNX1 plays a role in hematopoiesis and PTGS2 in 
inflammation and mitogenesis (Bye et al., 2011; Bye et al., 2012; 
Strickland et al., 2012).
Nine of the 25 associated SNPs were from small studies with 
fewer than 150 cases and controls. These SNPs are in the following 
TABLE 4 | Continued
Gene Variant (rs 
number)
Study (PMID) Population ESCC Controls Effect 
allele
Findings and  
Comments2
n MAF n MAF
RUNX1 rs2014300 (A/G) Bye et al., 2012 
(22865593)
Black South African 407 0.378 849 0.403 NS
Bye et al., 2012 
(22865593)
Mixed ancestry 
South African
257 0.438 860 0.370 G OR = 1.33 (1.09–1.63); 
p = 0.0055
rs2014300 (A/G) Chen et al., 2019 
(30753320)
Black South African4 591 0.38 852 0.40 NS
Chen et al., 2019 
(30753320)
Black South African5 880 0.36 939 0.36 NS
rs2834718 (T/A) Chen et al., 2019 
(30753320)
Black South African5 880 0.33 939 0.33 NS
SLC11A1 -237C/T Zaahl et al., 2005 
(15860357)
Mixed ancestry 
South African
105 0.029 110 0.1 p < 0.004
-8G/A Zaahl et al., 2005 
(15860357)
Mixed ancestry 
South African
105 0.004 110 0.009 NS
IVSI-28C/T Zaahl et al., 2005 
(15860357)
Mixed ancestry 
South African
105 0.028 110 0.0004  p < 0.05
GT-repeat Zaahl et al., 2005 
(15860357)
Mixed ancestry 
South African
0.171 0.191 NS
SULT1A1 638G/A in Exon 7 Dandara et al., 2006 
(16272171)
Black South African 145 0.42 194 0.37 NS1
Dandara et al., 2006 
(16272171)
Mixed ancestry 
South African
100 0.40 94 0.29 NS
TMEM173 rs13181561 (A/G) Chen et al., 2019 
(30753320)
Black South African5 880 0.48 939 0.49 NS
rs13153461 (G/A) Chen et al., 2019 
(30753320)
Black South African4 591 0.04 852 0.05 NS
TP53 16-bp insertion in 
intron 3
Vos et al., 2003 
(12550754)
Black South African 74 0.108 118 0.364
rs200073907
(Exon 4 codon 
34)
Vos et al., 2003 
(12550754)
Black South African 74 0.115 118 0.102 NS
rs750578863
(Exon 4 codon 
36)
Vos et al., 2003 
(12550754)
Black South African 73 0.089 115 0.143 NS
Arg72Pro Vos et al., 2003 
(12550754)
Black South African 73 0.356 115 0.409 p < 0.05
Arg72Pro Eltahir et al., 2012 
(23053979)
Sudanese 25 0.49 235 0.51 NS
rs1800371 (G/A) Chen et al., 2019 
(30753320)
Black South African4 591 0.02 852 0.03 NS
Chen et al., 2019 
(30753320)
Black South African5 880 0.03 939 0.02 NS
XBP1 rs2239815 (C/T) Chen et al., 2019 
(30753320)
Black South African4 591 0.21 852 0.16 T OR = 1.41 (1.15–1.74)
p = 0.001
Chen et al., 2019 
(30753320)
Black South African5 880 939 NS
1Increased risk among smokers with SULT1A1*2/*2 genotype, but sample size was small.
2When OR > 1, effect allele = increased risk; when OR < 1, effect allele = protective effect.
3rs3765525 has been merged into rs959421.
4Western and Eastern Cape Province Black Population.
5Gauteng Province Black Population.
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six genes: ADH3, AR, CP, CYP3A5, SLC11A1, and TP53. Because 
of the small sample size, the reliability and replicability of these 
results are uncertain. Sixteen of the SNPs came from studies with 
at least 150 cases and controls, and one study with 142 cases. 
These sample sizes could potentially give reliable and replicable 
results. The 16 SNPs were from the following genes: ADH1B, 
ALDH2, CASP8, CHEK2, CYP2E1, GSTT2B, MGMT, MLH3, 
MSH3, NAT2, PLCE1, PMS1, PTGS2, and RUNX1.
Two of the 16 SNPs are in the ALDH2 gene and were analyzed 
in two different studies. However, it is not clear whether these 
two SNPs are the same because, while one study reported the 
NCBI rs number (rs886205) (Bye et al., 2011), the other study 
did not (Li et al., 2008).The two SNPs reported very different 
MAF, and opposite odds ratios of 2.35 and 0.70 demonstrating 
increased risk and a protective effect, respectively.
Six of the 16 SNPs were reported to reduce the risk of ESCC, 
and they are the following: ADH1B (Arg48His; rs1229984), 
ALDH2 (+82 A > G; rs886205), GSTT2B (deletion allele), NAT2 
(341T > C; rs1801280), PTGS2 (-1195 A > G; rs689466), and 
PLCE1 (Arg548Leu; rs17417407). The remaining 10 SNPs were 
reported to increase the risk of ESCC: ALDH2 (ALDH2*1/*2), 
CASP8 (Asp302His; rs1045485), CHEK2 (rs4822983 C > T, and 
rs1033667, C > T), CYP2E1 (7632T > A), MGMT (Leu84Phe; 
rs12917), MLH3 (Arg797His; rs28756991), MSH3 (Ala1045Thr; 
rs26279), PMS1 (c.-21+639G > A; rs5742938), and RUNX1 
(rs2014300). Eleven of the 16 SNPs showed association in the 
South African Admixed population, while only four showed 
association in the Black South African population and one in 
a combined South African population. All the studies used 
PCR-based methods for genotyping. Using the 1000 Genomes 
Database, r2 analysis was carried out on SNPs reported in the 
same gene, to assess the LD between the SNPs. Thirteen pairs of 
SNPs in MHS2, CP, MSH3, PLCE1,CHEK2, and NAT1 genes had 
r2 > 0.45, shown in Figure 2 and Table S3.
Altogether 44 somatic changes were reported in the following 
22 genes: AR, CCND1, CDKN2A, COL1A2, EFGR, EP300, FAT1, 
FAT2, FAT3, FAT4, FBXW7, JAG1, KMT2C (MLL3), KMT2D 
(MLL2), MUC2, NFE2L2, NOTCH1, NOTCH3, PIK3CA, 
SERPINB4, TP53, and TP63, and six genetic loci without 
specific gene names (Table 6). The specific locus positions 
with the corresponding microsatellite markers are as follows: 
2p (D2S123), 3p13 (D3S659), 3p24.2-25 (D3S1255), 4q12 (Bat 
25), 2p21-p16.3 (Bat 26), and 1p12-13.3 (Bat 40). These variants 
were reported in the South African (20 variants), Kenyan (three 
variants), and Malawian (21 variants) populations. While the 
majority of the studies used PCR-based methods, a more recent 
study used WES as the analysis method (Liu et al., 2016). A total 
of 18 of the 22 genes with somatic variants in cancer tissue were 
TABLE 5 | Biological pathways for genetic susceptibility studies showing putative association with ESCC in African populations.
Gene Full name Pathway
ADH1B Alcohol dehydrogenase 1B (class I), beta 
polypeptide
Ethanol metabolism 
ADH3 Alcohol dehydrogenase ADH3 Metabolizes ethanol into acetaldehyde
ALDH2 Aldehyde dehydrogenase 2 family member Alcohol metabolism. Implicated in increased susceptibility for cancer
AR Androgen receptor Regulates binding of androgens on androgen receptor
CASP8 Caspase 8 Cell apoptosis
CHEK2 Checkpoint kinase 2 Tumor suppressor gene. Mutations associated with predisposition to carcinogenesis
CP Ceruloplasmin Peroxidation of iron through its transportation from organs and tissue into blood
CYP2E1 Cytochrome P450 family 2 subfamily E 
member 1
Drug metabolism and catalysis and synthesis of cholesterol, steroids, and other lipids. Implicated in 
cancer development
CYP3A5 cytochrome P450 family 3 subfamily A 
member 5
Involved in drug metabolism and in the synthesis of cholesterol, steroids, and other lipids
GSTT2B Glutathione S-transferase theta 2B (gene/
pseudogene)
Conjugation of glutathione to electrophilic and hydrophobic compounds. Plays a role in carcinogenesis
MGMT O-6-methylguanine-DNA methyltransferase DNA repair and defense from alkylating agents which cause mutagenesis and toxicity. Implicated in 
several cancers.
MLH3 MutL homolog 3 Maintenance of genomic integrity following cell division and DNA replication. Germline mutations 
implicated in cancer and somatic mutations implicated in microsatellite instability
MSH3 MutS homolog 3 Forms heterodimers with MSH2. Involved in mismatch repair and implicated in cancer development.
NAT2 N-acetyltransferase 2 Activation and deactivation of arylamine and hydrazine drugs and carcinogens. Implicated in high 
cancer incidence and drug toxicity.
PTGS2 Prostaglandin-endoperoxide synthase 2 A dioxygenase and a peroxidase involved in both inflammation and mitogenesis
PLCE1 Phospholipase C epsilon 1 Regulation of cell growth, differentiation, and gene expression.
PMS1 PMS1 homolog 1, mismatch repair system 
component
Mismatch repair gene. Mutations implicated in cancer development.
RUNX1 Runt related transcription factor 1 Development of hematopoiesis
SLC11A1 Solute carrier family 11 (proton-coupled 
divalent metal ion transporter), member 1
Regulation of gene expression.
TMEM173 Transmembrane protein 173 Regulation of the innate immune response to viral and bacterial infections. Role in tumorigenesis still 
inadequate
TP53 Tumor protein 53 Regulation of gene expression, cell cycle, apoptosis, and DNA repair. 
XBP1 X-box binding protein 1 Regulation of genes involved in endoplasmic reticulum protein synthesis, folding, glycosylation, redox 
metabolism, autophagy, lipid biogenesis, and vesicular trafficking. Associated with development of 
cancer.
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discovered using WES. Statistical significance was not reported 
for any of the 44 variants. The most common type of somatic 
variants was missense mutations, reported in 14 of the 22 genes 
(64%) (Patel et al., 2011; Liu et al., 2016). Other somatic changes 
included copy number gains (14%), copy number losses (5%), 
deletions (14%), insertions (14%), and frameshift mutations 
(14%). In three studies (Dietzsch and Parker, 2002; Dietzsch 
et  al., 2003; Naidoo et al., 2005), microsatellite instability and 
loss of heterozygosity (LOH) were reported (14%).
Table 7 shows a summary of the pathways in the 22 genes 
reporting somatic changes. Five genes, AR, EP300, KMT2D, 
KMT2C, and TP53, play a role in the regulation of transcription 
(Gamieldien et al., 1998; Dietzsch et al., 2003; Vos et al., 2003; Patel 
et al., 2011; Liu et al., 2016). The encoded protein for the AR gene 
functions as a steroid hormone activated transcription factor, while 
KMT2D has a role in methylation. Both TP53 and EP300 have been 
implicated in a number of cancers (Gamieldien et al., 1998; Vos et al., 
2003; Patel et al., 2011; Liu et al., 2016). TP53 additionally functions 
in DNA repair, gene expression, and apoptosis. The mismatch repair 
genes also facilitate DNA repair (Naidoo et al., 2005). CCND1, 
CDKN2A, FAT1/2/3/4, and Ras genes are all reported to be involved 
in cell cycle pathways including regulation of mitotic events, cell 
proliferation, and cell growth and death (Victor et al., 1990; 
Gamieldien et al., 1998; Liu et al., 2016). NOTCH1 and NOTCH3 
both facilitate cell and tissue development (Liu et al., 2016). JAG1 
plays a role in hematopoiesis while NFE2L2 is involved in response 
to inflammation including production of free radicals (Liu et al., 
2016). PIK3CA is an oncogene implicated in tumor development 
while SERPINB4 modulates response against tumor cells (Liu et 
al., 2016). EGFR and COL1A2 genes encode for epidermal growth 
factor and type 1 collagen, respectively (Dietzsch and Parker, 2002; 
Liu et al., 2016). FBXW7 is a tumor suppressor involved in ubiquitin 
degradation (Liu et al., 2016). MUC2 facilitates the formation of a 
mucous barrier that protects the gut lumen (Liu et al., 2016). TP63 
gene is involved in tissue and organ development including skin 
and heart, and in adult stem cell regulation (Liu et al., 2016).
FIGURE 2 | Linkage disequilibrium (LD) plot for paired SNPs. We obtained the rs numbers of the variants from dbSNP (version 152; April 2019; (https://www.ncbi.
nlm.nih.gov/snp/)) and used the canonical SNP identifier. To determine the LD between the SNPs, we obtained the imputed data set from the Thousand Genomes 
project (1000 Genomes Release Phase 3 2013-05-02) and used bcftools to extract all individuals from African populations not including African Americans, and the 
77 SNPs discussed here using all synonyms (alternative rs IDs) for SNPs (Auton et al., 2015). We obtained a dataset of 504 individuals and 67 SNPs. We computed 
all pair-wise r2 using PLINK (v1.09) (Danecek et al., 2011; Chang et al., 2015).
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Interaction Studies
Combinations of specific genotypes with environmental factors 
were also reported to be associated with ESCC in a number of 
studies (Table 2). The main two environmental factors studied 
were smoking and alcohol consumption. The interaction between 
smoking and alcohol status and specific genotypes was measured 
and reported as frequency (percentage) and assessed using p 
values and odds ratios in nine genetic susceptibility studies 
(Dandara et al., 2005; Li et al., 2005; Li et al., 2010; Dandara et al., 
2006; Li et al., 2008; Li et al., 2010; Bye et al., 2011; Matejcic et al., 
2011; Vogelsang et al., 2012; Matejcic et al., 2015). Four studies 
showed statistically significant associations between both alcohol 
and smoking status and variants in the CYP3A5, CYP2E1, GST, 
and NAT2 genes (Dandara et al., 2005; Li et al., 2005; Matejcic et 
al., 2015). SULT1A1 variants were associated with smoking status 
only (Dandara et al., 2006). Other interaction studies included 
wood/charcoal use and mutations in  the GST genes (Li et al., 
2010), as well as red and white meat intake and SNPs in NAT1/2 
genes (Matejcic et al., 2015).
DISCUSSION
General Systematic Review Findings
In this study, we systematically evaluated the genetic variants 
reported to be associated with ESCC in African populations 
providing the first systematic review on genetic factors of ESCC 
in this region. Of all studies that have been published on genetic 
association to ESCC in the African populations, only 23 fit our 
selection criteria. It was clear from the beginning that there is 
a dearth of information on this topic. Our analysis showed that 
25 germline SNPs were reported to be associated with ESCC in 
the South African population. However, none of these SNPs were 
TABLE 6 | Summary of studies investigating somatic changes linked to ESCC in African patients.
Gene Study (PMID) Population Findings
AR Dietzsch et al., 2003 (12925954) Black and mixed ancestry 
South African 
LOH at CAG locus
CCND1 Liu et al., 2016 (29148985) Malawian Enriched copy number gains
CDKN2A Gamieldien et al., 1998 (9808520) Black South African Insertions
Deletions
Frameshift mutations
Liu et al., 2016 (29148985) Malawian Copy number losses
COL1A2 Dietzsch and Parker, 2002 (12435113) Black South African LOH (promoter and 1st intron)
No evidence of MSI or allelic amplification
EFGR Liu et al., 2016 (29148985) Malawian Copy number gains
EP300 Liu et al., 2016 (29148985) Malawian Missense mutations
FAT1 Liu et al., 2016 (29148985) Malawian Nonsense mutations
FAT2 Liu et al., 2016 (29148985) Malawian Missense mutations
FAT3 Liu et al., 2016 (29148985) Malawian Missense mutations
FAT4 Liu et al., 2016 (29148985) Malawian Missense mutations
FBXW7 Liu et al., 2016 (29148985) Malawian Frameshift mutations
JAG1 Liu et al., 2016 (29148985) Malawian Missense mutations
KMT2C (MLL3) Liu et al., 2016 (29148985) Malawian Missense mutations
KMT2D (MLL2) Liu et al., 2016 (29148985) Malawian Nonsense mutations
Mismatch repair 
genes
Naidoo et al., 2005 (15735161) South African LOH and MSI at:
• D2S123 (2p)
• D3S659 (3p13)
• D3S1255 (3p3p24.2-25)
• Bat 25 (4q12)
• Bat 26 (2p2p21-p16.3)
• Bat 40 (1p12-13.3)
MUC2 Liu et al., 2016 (29148985) Malawian Missense mutations
NFE2L2 Liu et al., 2016 (29148985) Malawian Missense mutations
NOTCH1 Liu et al., 2016 (29148985) Malawian Missense mutations
NOTCH3 Liu et al., 2016 (29148985) Malawian Missense mutations
PIK3CA Liu et al., 2016 (29148985) Malawian Missense mutations
Ras genes Victor et al., 1990 (2199031) South African No mutations found in codon 12, 13 or 61
SERPINB4 Liu et al., 2016 (29148985) Malawian Missense mutations
TP53 Liu et al., 2016 (29148985) Malawian Missense and nonsense mutations
Gamieldien et al., 1998 (9808520) Black South African Exon 5–8 frameshift mutations: point mutations,
deletions and insertions 
Patel et al., 2011 (22040862) Kenyan Exon 5–8 mutations: missense, nonsense and deletions 
Vos et al., 2003 (12550754) South African 16-bp insertion in intron 3
Vos et al., 2003 (12550754) South African Exon 4 polymorphism in codons 34, 36 and 72
LOH (16-bp repeat locus)
TP63 Liu et al., 2016 (29148985) Malawian Copy number gains
LOH, loss of heterozygosity; MSI, microsatellite instability.
Genetics of Esophageal Carcinoma in AfricaSimba et al.
17 August 2019 | Volume 10 | Article 642Frontiers in Genetics | www.frontiersin.org
repeated in three or more independent studies; hence, a meta-
analysis was not possible. Additionally, only three (ALDH2, PLCE 
and CYP2E1) of the 20 genes were analyzed in two independent 
studies, but testing for different SNPs. We determined that it 
was unlikely that the two ALDH2 SNPs analyzed were the same 
SNPs. This is because the MAFs were significantly different and, 
while one SNP had a protective effect (reduced risk), the other 
increased risk. The lack of studies re-assessing the same genetic 
variants poses a major hurdle in validating existing evidence on 
the association between genetic variants and ESCC development. 
This makes resolving the genetic etiology of ESCC in African 
populations difficult.
Genetic Susceptibility to ESCC
Of the 25 SNPs from the genetic susceptibility studies that showed 
an association to ESCC, we concluded that results on 16 SNPs 
had the potential to be reliable and reproducible due to the larger 
sample sizes. Ten of the SNPs were reported to increase the risk 
of ESCC, while six were reported to reduce the risk. However, 
it was noted that the majority (11) of these SNPs showed 
association in the South African Admixed population and the 
studies did not report controlling for population stratification. 
This is a highly admixed population (Chimusa et al., 2013), in 
which the predominant ancestral lines are Khoesan (32–43%), 
Bantu-speaking Africans (20–36%), European (21–28%), and 
Asian (9–11%) (De Wit et al., 2010). This diverse population is a 
result of South Africa’s colonial and trade history, and constitutes 
9% of the total South African population (De Wit et al., 2010). 
Genetic variability can also be seen in the Black South African 
population (Chimusa et  al., 2013). Without controlling for 
population stratification, the reproducibility of these results is 
questionable. It is, however, important to note that the majority of 
these studies were carried out several years ago, and information 
on population stratification and methods to detect it may not 
have been available as yet.
Re-examination of common SNPs from the Chinese 
population was done in three of the studies (Bye et al., 2011; 
Bye et al., 2012; Chen et al., 2019), but the findings were 
not conclusive. It is possible that there may be population-
specific differences influencing the genetic etiology of ESCC 
in the African populations. This may also point to the role of 
environmental factors contributing to the genetic susceptibility 
to ESCC through gene-environment interactions.
TABLE 7 | Biological pathways for somatic changes studies showing putative association with ESCC in African populations.
Gene Full name Pathway
AR Androgen receptor gene Regulation of gene expression and the protein functions as a steroid-hormone activated 
transcription factor.
CCND1 Cyclin D1 Regulators of CDK kinases and mitotic events. Mutations and overexpression of the gene has 
been associated with cancer development.
CDKN2A Cyclin dependent kinase inhibitor 2A A tumor suppressor gene which regulates the cell cycle. Commonly inactivated in a variety of 
tumors.
CHEK2
COL1A2 Collagen type I, alpha 2 chain Encodes for type I collagen, which is an abundant connective tissue protein and part of 
extracellular matrix.
EFGR Epidermal growth factor receptor Encodes for the growth factor epidermal growth factor receptor.
EP300 E1A binding protein p300 Encodes the adenovirus E1A-associated cellular p300 transcriptional co-activator protein which 
functions in transcription regulation. Mutations have been implicated in tumorigenesis.
FAT1/2/3/4 FAT atypical cadherin 1/2/3/4 Human homologues of the Drosophila FAT genes. Putative tumor suppressor involved in cell 
proliferation during Drosophila development.
FBXW7 F-box and WD repeat domain 
containing 7
Encodes an F-Box protein which binds directly to cyclin E and potentially targets cyclin E for 
ubiquitin-mediated degradation.
JAG1 Jagged 1 Encodes for the human homolog of the Drosophila jagged 1 protein which is involved in 
hematopoiesis.
KMT2C (MLL3) Lysine methyltransferase 2C The gene is member of the myeloid/lymphoid or mixed-lineage leukemia (MLL) family. It encodes 
a nuclear protein involved in transcriptional regulation.
KMT2D (MLL2) Lysine methyltransferase 2D Methylation of histones and transcriptional regulation.
Mismatch repair genes Mismatch repair genes DNA repair. Mutations have been implicated in cancer.
MUC2 Mucin 2, oligomeric mucus/gel-forming Formation of insoluble mucous barrier that protects the gut lumen.
NFE2L2 Nuclear factor, erythroid 2 like 2 Encodes for proteins involved in response to inflammation including free radical production.
NOTCH1 NOTCH1 Development of cell and tissue. Mutations have been reported to be linked with tumorigenesis. 
NOTCH3 NOTCH3 The third discovered human homologue of the Drosophila melanogaster type I membrane protein 
notch. Involved in intercellular signaling pathways in neural development.
PIK3CA Phosphatidylinositol-4,5-bisphosphate 
3-kinase catalytic subunit alpha
Oncogenic and implicated in cancer development.
Ras genes Rat sarcoma Regulation of cell signaling pathways, and cell growth and death.
SERPINB4 Serpin family B member 4 Inactivation of granzyme M, an enzyme that kills tumor cells. Highly expressed in tumor cells.
TP53 Tumor protein p53 Regulates transcription, expression of target genes, thereby inducing cell cycle arrest, apoptosis, 
senescence, DNA repair, or changes in metabolism. Implicated in a number of cancers.
TP63 Tumor protein p63 Involved in the following processes in skin development and maintenance, adult stem/progenitor 
cell regulation, heart development, and premature aging.
Genetics of Esophageal Carcinoma in AfricaSimba et al.
18 August 2019 | Volume 10 | Article 642Frontiers in Genetics | www.frontiersin.org
Somatic Changes in ESCC
Forty-four somatic variants were reported, but only two were 
significantly associated with ESCC. The paucity of information was 
also evident in the somatic variant studies. There were significantly 
fewer studies (8) on somatic variants than on genetic susceptibility 
(17). The molecular profiling of tumors is of great importance as 
it is relevant in the development of targeted cellular therapeutics. 
One gene (CDKN2A) was analyzed in two studies, but these studies 
focused on a different variant. Another gene, TP53, was analyzed 
in four studies, but two studies analyzed different parts of the gene, 
and two had no control data. It was evident, however, that the WES 
study provided with a wider variety of genetic variants associated 
with ESCC (Liu et al., 2016). The WES study overall had the largest 
number of genetic variants of all the 23 studies and was able to 
identify variants in an unbiased manner.
Common Limitations Among 
the African Studies
There were no GWAS among the studies we analyzed, but 
reports from the Chinese and European studies demonstrated 
that GWAS are able to successfully identify common genetic 
variants associated with ESCC (Abnet et al., 2017). To date, 
GWAS has successfully identified more than 700 loci for cancer 
risk. However, these studies have been predominantly done in 
populations of European ancestry (80%), with African and 
Latin American populations contributing less than 1% (Van 
Loon et al., 2018). A shift to WES and GWAS on the African 
populations might, therefore, yield better results in identifying 
variants that play a role in ESCC development. The African 
Esophageal Cancer Consortium, which was initiated in 2016 by 
African investigators and International partners, released a call 
to action to, among other priority activities, increase molecular 
research on esophageal cancer in Africa, particularly GWAS and 
genomic profiling (Van Loon et al., 2018).
One of the main deficiencies in the studies was that the 
majority of the genetic susceptibility studies did not report 
a power calculation, or a genotyping error, and this may have 
resulted in studies being underpowered and with increased type 
II error. Few studies reported correction for multiple testing; 
however, many of the studies were not analyzing multiple variants 
at the same time. The lack of correction for multiple testing, 
therefore, is not a reflection on the methodological quality. Very 
few studies reported NCBI rs numbers. In most studies, the 
diagnosis of ESCC in patients was adequately defined with no 
ambiguity on the number of patients with ESCC. There were, 
however, three studies that combined samples from patients with 
squamous cell and adenocarcinoma into one case group, which 
could introduce bias (Dietzsch et al., 2003; Eltahir et al., 2012; 
Vogelsang et al., 2012).
It is important to note that rs numbers were poorly 
documented in the majority of the studies assessed in this 
systematic review. Additionally, in many of these studies, the 
positions of the SNPs using genome coordinates were not 
reported, hence making it difficult to locate the SNPs. In the 
absence of an rs number, we recommend that authors report 
the position using genome coordinates and the version of the 
genome used as a reference.
The somatic variant studies also had adequately defined 
ESCC diagnosis for the majority of the studies. While the variant 
classification and type were reported by most studies, there was 
no confirmation of the results (except for two studies). Overall, 
for both the germline and somatic variant studies, the quality of 
reporting for the majority of the studies was not adequate. Other 
important limitations and biases are the lack of controlling for 
population stratification and small sample sizes in the study 
populations, which may have led to unreliable results.
Limitations of the Systematic Review
While we did a comprehensive search in four of the main 
literature databases, it is possible that we could have missed 
some non-English studies on African populations. Because of 
the lack of replication and validation studies, we could not carry 
out a meta-analysis in the current study. Furthermore, we did 
not re-analyze the data and relied on reported p values and odds 
ratios for descriptive analysis.
CONCLUSIONS
While this review has highlighted a number of genes that may 
be potentially associated with ESCC in the African populations, 
limitations such as lack of reproducibility, quality of reporting, and 
quality of assessment remain a major concern. The implications 
of having these inconsistencies and lack of reproducibility are that 
the genetic etiology of ESCC in Africa will continue to be unclear. 
The region lags behind in contributing to genetic knowledge and 
literature on ESCC. Importantly, any preventative, diagnostic, 
or therapeutic interventions cannot be effectively identified or 
applied in these populations.
The identification of genetic markers of esophageal cancer 
susceptibility has clear translational benefits to African 
populations in understanding the underlying disease risk and 
heritability. Benefits include the utilization of genetic information 
to improve risk prediction, which can be translated into prevention 
and screening programs relevant and specific to the African 
population. These studies also play a role in identifying and 
quantifying the interactions of modifiable environmental risk 
factors, which interact with these genetic variants, and hence 
provide a platform for better targeted interventions. The ability to 
sufficiently translate genetic research on the African population 
is dependent on more genetic studies done on the population.
Our recommendations are that more and larger genetic 
studies be done on the African populations, particularly focusing 
on WES and GWAS approaches. This will require multinational 
collaborations between the African countries.
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